Clinical trial
Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and…
NCT00256828 · Clinical Trial Agency of HIV Study Group, Other · Completed
Key facts
| NCT number | NCT00256828 |
|---|---|
| Title | Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV |
| Official title | A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03) |
| Lead sponsor | Clinical Trial Agency of HIV Study Group, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | didanosine + lamivudine + efavirenz |
| Enrollment | 360 |
| Start date | Jun 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Nov 22, 2005 |
| Last update posted | Oct 16, 2007 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: